- Joined
- 27 June 2010
- Posts
- 4,203
- Reactions
- 329
Aroa Biosurgery is a soft tissue regeneration company that commenced operations in 2008. Aroa focuses on improving the rate and quality of healing in complex wounds and soft tissue reconstruction.
From over 10 years of research and development, Aroa has developed Endoform®, a proprietary soft tissue regeneration technology platform. Endoform® can temporarily replace damaged tissue by acting as a scaffold in the wound or the soft tissue to grow new tissue. It is used where tissue has been lost or damaged by disease or injury. Currently, Aroa has five commercial products based on the Endoform® technology, alongside a new product development pipeline.
Aroa is based in Auckland, New Zealand, with an additional sales office and distribution function in the United States.
It is anticipated that ARX will list on the ASX on 30 July 2020.
https://aroabio.com
From over 10 years of research and development, Aroa has developed Endoform®, a proprietary soft tissue regeneration technology platform. Endoform® can temporarily replace damaged tissue by acting as a scaffold in the wound or the soft tissue to grow new tissue. It is used where tissue has been lost or damaged by disease or injury. Currently, Aroa has five commercial products based on the Endoform® technology, alongside a new product development pipeline.
Aroa is based in Auckland, New Zealand, with an additional sales office and distribution function in the United States.
It is anticipated that ARX will list on the ASX on 30 July 2020.
https://aroabio.com